Articles

Tunnah’s musings: the dangers of medical misinformation

24th April 2015

Tunnah’s musings: the dangers of medical misinformationPaul Tunnah

As he heads off to the US to speak about the democratisation of medical information at the 11th Annual Meeting of ISMPP, Paul Tunnah muses on the real danger of... Read more

Pharma gets social: Will ASCO 2015 be the most social congress meeting…

23rd April 2015

Pharma gets social: Will ASCO 2015 be the most social congress meeting ever?Daniel Ghinn

Next month, the 2015 ASCO Annual Congress takes place in Chicago. The American Society of Clinical Oncology congress meeting is one of the world's largest congress meetings, with 30,000 delegates.... Read more

7 Questions: Nick Bason on bowel cancer

22nd April 2015

7 Questions: Nick Bason on bowel cancerNick Bason

pharmaphorum speaks to the head of policy and communications at Bowel Cancer UK about the charity's progress in fighting the disease and the focus for future campaigns.What prompted you to... Read more

Rare disease groups: scaling up from the kitchen table

21st April 2015

Rare disease groups: scaling up from the kitchen tableFlóra Raffai

People wanting to establish rare disease support groups face lack of understanding and awareness from the medical profession, challenges finding others with the same condition, often little funding and no... Read more

News

AstraZeneca: UK medicines deal not delivering

24th April 2015

AstraZeneca: UK medicines deal not deliveringAndrew McConaghie

The head of AstraZeneca (AZ) in the UK says the country's deal on paying pharma for medicines is not delivering on its promises, and warned her firm would not sign... Read more

AbbVie sticking to HCV sales forecasts

24th April 2015

AbbVie sticking to HCV sales forecastsStaff reporter

AbbVie's combination hepatitis C virus (HCV) therapy Viekira Pak racked up sales of $231 million in its first quarter on the market, setting it on course for blockbuster revenues for... Read more

Boehringer hopes for new product boost after challenging 2014

23rd April 2015

Boehringer hopes for new product boost after challenging 2014Kevin Grogan

Boehringer Ingelheim (BI) has been reflecting on a challenging 2014 as currency-adjusted sales dipped 3.2 per cent to €13.30 billion. But the future looks bright for the German family-owned group... Read more

TiGenix on track for pivotal cell therapy results in Crohn's

23rd April 2015

TiGenix on track for pivotal cell therapy results in Crohn'sStaff reporter

Cell therapy specialist TiGenix is mere months away from reporting phase III trial results for its fistulising Crohn's disease candidate Cx601 that could support an EU marketing application early next... Read more

Audio & Video

Being Patient-centric is being Family-ce…

 

Cancer survivor and patient opinion leader Andrew Schorr and his wife Esther Schorr discuss how families should be involved in decision-making around care for patients.... View more

On demand webinar: Staring into the aby…

IMS webinar

 

Regardless of the colour of the next UK government that emerges as a result of the May election, the £30–50bn NHS budget... View more

Live Tweetchat: Managing COPD in the rea…

Tweetchat-600x400a

Working in partnership, Atlantis Healthcare and pharmaphorum present a Tweetchat focussed on the real world challenges patients face in managing their COPD,... View more

Live webinar/debate - Feb 4th - COPD, co…

Join the COPD webinar/debate

 

 

COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and is recognised... View more

White Papers

Optimising patient outcomes through phys…

Optimising patient outcomes through physician educationDr James Quekett

Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange. This white... View info

Is pharma brand marketing dead?

Is pharma brand marketing dead?Mark Sales, Fabrice Bourg & Richard Goosey

This comprehensive supplement brings together a series of articles, insights and discussions produced by Kantar Health in order to help stimulate debate and fresh thinking about the future of pharmaceutical... View info

Improved health and wellbeing in COPD

Improved health and wellbeing in COPDAna Maria Arboleda, Clare Maloney & Prof John Weinman

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them. This is not only... View info

Computer Gaming: The Future of Decision-…

Computer Gaming: The Future of Decision-Making for Life Sciences?

How can life science brands identify winning strategic decisions when there are so many variables to consider? One route is via 'road-testing' decisions ahead of sign-off under computer game simulated... View info

Further News & Articles

Renaissance for Pfizer antibody-drug conjugate?

Pfizer has scored a phase III trial success for its antibody-drug conjugate (ADC) inotuzumab ozogamicin in acute... Read more

News

Mylan set to fight Teva’s $40 billion takeover bid

Teva has unveiled its long-anticipated takeover bid for rival generics firm Mylan, offering a deal worth $40 ... Read more

News

Novartis data upsetting the CAR-T at AACR?

Shares in companies developing much-anticipated CAR-T category of immuno-oncology therapies have been under pres... Read more

News

Future of the NHS is number one issue – but will it swing the election?

As the UK's election day draws near, The Labour party is winning the battle to convince voters that its policies... Read more

News

Cardiovascular study sets Sanofi on course to refile Lyxumia

Sanofi's diabetes therapy Lyxumia has been given a clean bill of health in a cardiovascular outcomes trial, open... Read more

News

Merck targets high responders in Keytruda lung cancer filing

Merck has filed its immunotherapy drug Keytruda for use in lung cancer patients, and has pinpoint... Read more

News